{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 52,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 25,
  "notes": "The table highlights NVL-655's superior profile in G1202R and GRLM/GRGA/GRLF activity compared to existing therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/31",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.077,
        "y": 0.845
      },
      "kind": "disclaimer",
      "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-655. Clinical investigation of NVL-655 is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93a72426-f538-457d-9417-79473fd62672",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.49,
        "w": 0.85,
        "x": 0.077,
        "y": 0.34
      },
      "kind": "table",
      "text": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, and Lorlatinib across 5 activity categories.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed2502b6-378a-467c-88b8-d4761384af5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.077,
        "y": 0.188
      },
      "kind": "title",
      "text": "Differentiated Product Candidate for ALK-positive NSCLC patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8a4a186-eda8-4a1e-85de-b285025b4a88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.19,
        "x": 0.077,
        "y": 0.115
      },
      "kind": "title",
      "text": "NVL-655",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0079f001-c593-434a-98e6-45f65fd4b520",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "211b36f3-a2a9-465d-93e6-0f5638e1e0cf",
      "evidence": "components include table/data with 5 activity categories",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "a81405ed-39a6-47c7-9bf3-4f48ac74fc57",
      "evidence": "Grid-based comparison of product features against competitors",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 29,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5bd43550-4e7b-49ae-9310-ece1e67e14d2",
      "evidence": "Slides 29-40 present preclinical and clinical trial results for NVL-655.",
      "position": 1,
      "objective": "How can Nuvalent's therapies address the needs of patients with specific cancer mutations?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}